Edwards Lifesciences (EW) Expected to Announce Earnings on Tuesday

Edwards Lifesciences (NYSE:EW) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of $0.61 per share and revenue of $1.5425 billion for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 13, 2026 at 12:00 AM ET.

Edwards Lifesciences Stock Up 1.5%

Edwards Lifesciences stock opened at $82.58 on Tuesday. Edwards Lifesciences has a twelve month low of $65.94 and a twelve month high of $87.89. The business has a fifty day moving average of $84.72 and a two-hundred day moving average of $81.07. The firm has a market cap of $47.92 billion, a P/E ratio of 35.59, a P/E/G ratio of 3.13 and a beta of 0.94. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. UBS Group restated a “neutral” rating and set a $95.00 price objective (up from $92.00) on shares of Edwards Lifesciences in a research note on Monday, January 12th. Truist Financial set a $92.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, December 5th. Barclays reaffirmed an “overweight” rating and issued a $104.00 price objective (up previously from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. The Goldman Sachs Group reissued a “buy” rating and set a $108.00 target price on shares of Edwards Lifesciences in a research report on Friday, January 9th. Finally, Mizuho raised their target price on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $96.82.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the firm’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the transaction, the vice president directly owned 31,870 shares of the company’s stock, valued at approximately $2,729,984.20. This represents a 26.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 57,824 shares of company stock valued at $4,863,323. Insiders own 0.34% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Several large investors have recently added to or reduced their stakes in EW. Brighton Jones LLC purchased a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $266,000. NewEdge Advisors LLC lifted its stake in Edwards Lifesciences by 8.1% during the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after acquiring an additional 2,665 shares during the period. Sei Investments Co. boosted its holdings in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after acquiring an additional 58,988 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after purchasing an additional 50,924 shares during the last quarter. Finally, Treasurer of the State of North Carolina lifted its position in Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock valued at $21,028,000 after purchasing an additional 1,065 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.